



TITLE:

Fluvoxamine alleviates paclitaxel-induced neurotoxicity

AUTHOR(S):

Tanimukai, Hitoshi; Kudo, Takashi

CITATION:

Tanimukai, Hitoshi ...[et al]. Fluvoxamine alleviates paclitaxel-induced neurotoxicity. *Biochemistry and Biophysics Reports* 2015, 4: 202-206

ISSUE DATE:

2015-12

URL:

<http://hdl.handle.net/2433/202521>

RIGHT:

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).



Contents lists available at ScienceDirect

Biochemistry and Biophysics Reports

journal homepage: www.elsevier.com/locate/bbrep



Fluvoxamine alleviates paclitaxel-induced neurotoxicity

Hitoshi Tanimukai ^{a,b,*}, Takashi Kudo ^c

^a Department of Clinical Oncology, Pharmacogenomics, and Palliative Medicine, Graduate School of Medicine and Faculty of Medicine, Kyoto University, Japan

^b Palliative Care Center, Department of Palliative Medicine, Kyoto University Hospital, 54 Kawaharacho, Syogoin, Sakyou-ku, Kyoto City, Kyoto 606-8507, Japan

^c Department of Psychiatry, Osaka University Health Care Center, 1-17, Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan



ARTICLE INFO

Article history:

Received 4 May 2015

Received in revised form

15 September 2015

Accepted 21 September 2015

Available online 25 September 2015

Keywords:

Chemobrain

Paclitaxel

Endoplasmic reticulum stress

Fluvoxamine

Sigma 1 receptor

Selective serotonin reuptake inhibitor

ABSTRACT

Paclitaxel (Px) is an effective chemotherapeutic agent for the treatment of various cancers. However, it is often associated with neurological side effects, including chemotherapy-associated cognitive impairment (CACI), such as “chemobrain”. Previously, we reported that endoplasmic reticulum (ER) stress is involved in Px-induced neurotoxicity, and immunoglobulin heavy chain binding protein (BiP) inducer X (BIX) alleviates Px-induced neurotoxicity. However, BIX has not been used in clinical practice yet. We recently reported that fluvoxamine (Flv) alleviates ER stress via induction of sigma-1 receptor (Sig-1R). The purpose of this study was to investigate whether Flv could alleviate Px-induced neurotoxicity *in vitro*. SK-N-SH cells were pre-treated for 12 h with or without 10 µg/ml Flv followed by treatment with 1 µM Px with or without co-existence of 10 µg/ml Flv for 24 h. To investigate the involvement of Sig-1R in alleviation effect on Px-induced neurotoxicity, 1 µM NE100, an antagonist of Sig-1R, was added for 24 h. Neurotoxicity was assessed using the MTS viability assay and ER stress-mediated neurotoxicity was assessed by evaluating the expression of C/EBP homologous protein (CHOP), cleaved caspase 4, and cleaved caspase 3.

Pre-treatment with Flv significantly alleviated the induction of CHOP, cleaved caspase 4, and cleaved caspase 3 in SK-N-SH cells. At the same time, pre-treatment with Flv significantly induced Sig-1R in SK-N-SH cells. In addition, viability was significantly higher in Flv-treated cells than in untreated cells, which was reversed by treatment with NE100.

Our results suggest that Flv alleviates Px-induced neurotoxicity in part through the induction of Sig-1R. Our findings should contribute to one of the novel approaches for the alleviation of Px-induced neurotoxicity, including chemobrain.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Cancer treatments, including chemotherapy, radiation therapy, and targeted biological therapies, have made great advances in the last century and have led to improved survival. However, their administration is often associated with several side effects and may reduce patient quality of life (QOL). Cognitive impairment is among the most frequently reported problems by patients during

Abbreviations: BiP, immunoglobulin heavy-chain binding protein; BIX, BiP inducer X; CACI, chemotherapy-associated cognitive impairments; CHOP, C/EBP homologous protein; CYP, cytochrome P450; ER, endoplasmic reticulum; Flv, fluvoxamine; JNK, c-Jun NH2-terminal kinase; Px, paclitaxel; QOL, quality of life; Sig-1R, sigma 1 receptor; SSRI, selective serotonin reuptake inhibitor; UPR, unfolded protein response

* Corresponding author at: Palliative Care Center, Department of Palliative Medicine, Kyoto University Hospital, 54 Kawaharacho, Syogoin, Sakyou-ku, Kyoto City, Kyoto 606-8507, Japan. Fax: +81 757514423.

E-mail address: tanimuki@kuhp.kyoto-u.ac.jp (H. Tanimukai).

<http://dx.doi.org/10.1016/j.bbrep.2015.09.014>

2405-5808/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

the treatment, especially in the context of chemotherapy. This cognitive impairment related to chemotherapy is known as “chemofog” or “chemobrain” and is well studied in breast cancer patients. Reports demonstrate that 15–75% of breast cancer survivors have cognitive impairment in the domain of memory, processing speed, attention, and executive function [1–4]. Multiple hypotheses exist regarding chemobrain, including disruption of hippocampal cell proliferation and neurogenesis [5], chronic increases in inflammation [6,7], increased oxidative stress [6], white matter disruption [8,9], and long-term changes in cerebral blood flow and metabolism [10]. However, a detailed mechanism and intervention for CACI have not been established.

Paclitaxel (Px) is a taxane agent that binds microtubules, stabilizes microtubule dynamics, and arrests the cell at the mitotic phase [11]. However, Px often induces side effects such as arthralgia, myalgia, and ataxia. In addition, pronounced emotional distress, including depression, and reduced mental QOL through adjuvant treatment has recently been reported [12]. Though, it is

believed that Px is prevented from penetrating into the brain, a positron emission tomography study demonstrated detectable levels of radiolabeled Px in the brain after intravenous administration [13], indicating that Px may directly influence the central nervous system.

The endoplasmic reticulum (ER) stress response, also called the unfolded protein response (UPR), is a defense system that deals with the accumulation of unfolded proteins in the ER lumen. However, when ER stress is very severe, cells induce and/or activate C/EBP homologous protein (CHOP), the c-Jun NH2-terminal kinase (JNK) pathway, and caspase 4, which lead to apoptosis. Accumulating evidence demonstrates the importance of ER stress and of UPR in the pathophysiology of human neurological diseases, such as Parkinson's disease [14,15], Alzheimer's disease [15–18], and causes of cognitive dysfunction. Recently, we reported that ER stress is involved in Px-induced neurotoxicity [19]. In addition, we have also reported that immunoglobulin heavy-chain binding protein (BiP) inducer X (BIX) attenuates Px-induced neurotoxicity through alleviation of ER stress [19]. The effect of BIX in the alleviation of ER stress has been reported in many other situations [20–25]. However, BIX has not been approved for clinical practice use yet and is only permitted for experimental use. Thus, the exploration of agents like BIX in drugs that have already been licensed for the clinical setting should be fast way to practical use.

Recently, we reported that fluvoxamine (Flv), a selective serotonin reuptake inhibitor (SSRI) that is widely used in clinical practice as an antidepressant, alleviates ER stress *in vitro* and in animal experiments [26].

In the present study, we investigated the effect of Flv on Px-induced neurotoxicity using SK-N-SH cells *in vitro*.

2. Materials and methods

2.1. Chemicals

Flv (Sigma-Aldrich, St. Louis, MO, USA) and NE100 (Santa Cruz Biotechnology, Dallas, Texas, USA) were dissolved in double-distilled water (DDW). Px (Sigma) was dissolved in dimethyl sulfoxide (DMSO).

2.2. Cell culture

SK-N-SH neuroblastoma cells were grown in Dulbecco's Modified Eagle's Medium (DMEM; GIBCO/Invitrogen Life Technologies, Paisley, UK) with 10% fetal bovine serum (FBS; JRH, Woodland, CA, USA). Cells were maintained at 37 °C in an incubator within an atmosphere of 5% carbon dioxide (CO₂). Cells were routinely passaged using trypsin (0.25%)–EDTA (0.1%) solution in Hank's Balanced Salt Solution (HBSS; Himedia Laboratories Pvt. Ltd., Mumbai, India).

2.3. MTS cell viability assays

Cellular viability was assessed using CellTiter 96 Aqueous One Solution Cell Proliferation Assays (Promega, Madison, WI, USA). Briefly, SK-N-SH cells were seeded in 96-well plates. Cells were allowed to attach for 24 h. For evaluation of the toxicity of Flv on SK-N-SH cells, cells were treated with 10, 25, 50, 75, or 100 µg/ml Flv for 24 h at 37 °C. For evaluation of the alleviation effect of Flv on Px-induced neurotoxicity, SK-N-SH cells were pre-treated with or without 10 µg/ml Flv for 12 h followed by 1 µM Px treatment with or without 10 µg/ml Flv for 24 h. To confirm the involvement of Sig-1 R in alleviation effect on Px-induced neurotoxicity, SK-N-SH cells were incubated with 1 µM Px, 10 µg/ml Flv and 1 µM NE100 for 24 h. Next, 20 µl of MTS reagent was added to each well

and cells were incubated for 2 h. Optical density was measured at 490 nm using a Micro Plate Reader (Bio-Rad, Hercules, CA, USA).

2.4. Western blots

SK-N-SH cells were pre-treated with or without 10 µg/ml Flv for 12 h followed by 1 µM Px treatment with or without 10 µg/ml Flv for 24 h at 37 °C. Cells were washed in Tris-buffered saline (TBS), harvested, and lysed in RIPA buffer (Thermo Fisher Scientific, Inc., Rockford, IL, USA) with a protease inhibitor cocktail (Roche, Mannheim, Germany), and a phosphatase inhibitor cocktail (Roche). Lysates were sonicated on ice three times for five seconds each, and then incubated for 15 min. After centrifugation for 20 min at 13,000 g, supernatants were retained and boiled in SDS sample buffer. Lysates (10 µg) were separated on SDS-polyacrylamide gels and transferred to polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). Non-specific protein binding was blocked by incubating membranes for 1 h at room temperature in 5% w/v non-fat milk powder in TBS-T [50 mM Tris-HCl (pH 7.6), 150 mM NaCl, and 0.1% v/v Tween-20]. The membranes were incubated overnight at 4 °C with the following primary antibodies: anti-CHOP (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-caspase 4 (1:500; Medical and Biological laboratories, Nagoya, Japan), anti-caspase 3 (1:1000; Cell Signaling Technology, Boston, MA, USA), anti-sigma 1 receptor (Sig-1R) (1:250; Abcam, Cambridge, UK) and anti-GAPDH (1:1000; Thermo Fisher Scientific, Waltham, MA, USA). The membranes were then washed three times in TBS-T for 5 min. Finally, the membranes were incubated for 60 min at room temperature with HRP-conjugated anti-rabbit or anti-mouse antibodies (Promega, Madison, WI, USA). Protein bands were detected using the ECL Plus kit (GE Healthcare, Buckinghamshire, UK). The intensity of each band was quantified using NIH image J software.

2.5. Statistical analyses

Data are presented as mean values ± standard deviation (SD). Unpaired student's *t*-test or one-way analysis of variance (ANOVA) followed by Tukey–Kramer test were used to determine the levels of significance between sample means. All results are representative of at least three independent experiments.

3. Results

3.1. Flv toxicity on SK-N-SH cells

The toxicity of Flv on SK-N-SH cells was examined using an MTS assay. We used 10, 25, 50, 75, or 100 µg/ml Flv or a vehicle control to treat SK-N-SH cells. SK-N-SH cells treated with Flv showed 80% (25 µg/ml), 29% (50 µg/ml), 19% (75 µg/ml), and 18% (100 µg/ml) viability compared to the vehicle control cells ($p < 0.001$ at all doses) (Fig. 1). However, SK-N-SH cells treated with 10 µg/ml Flv did not show reduced viability (102%) compared to the vehicle control (Fig. 1). Based on these data, we used 10 µg/ml Flv in all subsequent experiments.

3.2. Flv alleviates Px-induced ER stress mediated apoptosis

Next we investigated whether Flv could alleviate Px-induced ER stress-mediated apoptosis in SK-N-SH cells by monitoring CHOP, cleaved caspase 4, and cleaved caspase 3, an active form of each caspase. CHOP, cleaved caspase 4, and cleaved caspase 3 were induced in cells treated with Px compared to control cells (Fig. 2a–c, $[p < 0.01]$ at each comparison), which is consistent with our previous report [19]. On the other hand, when cells were pre-




Fig. 1. Flv toxicity in SK-N-SH cells. Flv was added to SK-N-SH cells at the indicated dose. Cell toxicity was assessed using an MTS assay 24 h later. DDW was applied as the vehicle control. The relative ratio compared with the absorbance of the vehicle control (0 µM) is indicated. Histograms shows the mean \pm SD from six independent experiments. * $p < 0.001$ (Student's *t*-test).

treated with Flv followed by co-treatment with Px/Flv for 24 h, the induction of CHOP, cleaved caspase 4 and cleaved caspase 3 were alleviated compared to the Flv-untreated cells (Fig. 2a–c, $p < 0.05$, $p < 0.05$, and $p < 0.01$, respectively). We next investigated the induction of Sig-1R by Flv in SK-N-SH cells. Flv has been reported not only as a potent Sig-1R agonist with stronger affinity than other SSRIs [27], but also as an inducer of Sig-1R [26]. Sig-1R was induced in cells treated with Flv for 12 h compared to untreated cells (Fig. 2d, $p < 0.05$). This induction continued for at least 24 h (Fig. 2e, $p < 0.01$).

3.3. Flv alleviates Px-induced neurotoxicity through Sig-1R

Finally, using a MTS assay, we quantitatively assessed whether Flv can alleviate Px-induced neurotoxicity. Similar to the results from Western blots, the viability that was decreased by Px treatment was recovered in Flv-pre-treated cells compared to Flv-untreated cells (Fig. 3, $p < 0.05$). This recovery was reversed when cells were incubated with Px, Flv and NE100 (Fig. 3, $p < 0.05$).

4. Discussion

In the present study, we investigated the neuroprotective effects of Flv on Px-induced neurotoxicity. We have clearly demonstrated that Flv alleviates the Px-induced ER stress-mediated apoptosis. We have also shown that the alleviation effect of Flv is

due to the possible involvement of Sig-1R induction that is characteristic in Flv. These data suggest that Flv may be a candidate drug for the alleviation of Px-induced neurological side effects.

We have shown that a low dose of Flv (10 µg/ml) does not affect the viability of SK-N-SH cells. On the other hand, viability in both cells gradually decreases in a dose-dependent manner. Recently, the possible anti-cancer properties of antidepressants, including SSRIs, was reported, and increased interest within the scientific community [28–30]. Our results from experiments using a high dose of Flv (≥ 25 µg/ml) correspond with previous reports.

Px is a taxane agent and neurotoxicity is one of its most prominent side effects, leading to peripheral neuropathy in many patients. On the other hand, Px could also cause pronounced emotional distress, including depression [12], and/or cognitive dysfunction because detectable levels of radiolabeled Px was found in the brain by a positron emission tomography [13]. Several putative hypotheses regarding Px-induced neurotoxicity, such as abnormal aggregation of microtubules in neuronal cells and direct injury of neuronal cells through intrinsic cells are being considered. We have previously reported that Px-induced ER stress mediates neuronal apoptosis and BIX attenuates its neurotoxicity through alleviation of ER stress [19]. In the present study, we have demonstrated that pre-treatment with 10 µg/ml Flv, instead of BIX, significantly alleviates Px-induced CHOP, cleaved caspase 4, and cleaved caspase 3 (Fig. 2a–c). These results indicate that Flv alleviates Px-induced ER stress-mediated apoptosis. This tendency was also seen in the results of the MTS assay (Fig. 3). A similar result has been reported in human neuroblastoma SH-SY5Y cells treated with tunicamycin, an ER stress-inducing reagent [31]. However, the authors did not suggest how Flv alleviates ER stress. Recently, we have reported that Flv alleviates ER stress via induction of Sig-1R [26]. Sig-1R, which is expressed on ER membranes, has recently been discovered and shown to have neuroprotective activity as a molecular chaperone regulating protein folding and degradation at the ER [32–35]. Furthermore, growing evidence suggests that Sig-1R plays an important role in neuronal plasticity, a process implicated in the pathophysiology of neuropsychiatric diseases, such as major depressive disorder and schizophrenia. Thus, Sig-1R receptor may be a novel therapeutic target for neuropsychiatric diseases and disorders [36–39]. Similar to that of our previous report, the expression of Sig-1R was induced in SK-N-SH cells treated by 10 µg/ml Flv after 12 h (Fig. 2d) and the induction continued for at least 24 h (Fig. 2e). In addition, the alleviation effect of Flv on Px-induced neurotoxicity was reversed by NE100 (Fig. 3). Based on our previous and present results, Sig-1R is involved in the alleviation of Px-induced neurotoxicity.

Previous study demonstrated that Px-treated mice exhibit mechanical allodynia on days 3–15 of Px administration [40]. Interestingly, Flv administration for 5 days weakly but significantly attenuated Px-induced allodynia. Although, we only performed a cellular model and focused on the Px induced ER stress related neurotoxicity in the present study, our previous animal study has demonstrated that Flv treatment suppressed cerebral infarction size in mice after focal cerebral ischemia [26]. Because cerebral ischemia also induces ER stress [41], Flv could alleviate Px induced ER stress related neurotoxicity in the brain. Further *in vivo* studies, including cognitive behavioral evaluation in Px-injected mice, are needed to support our study.

In conclusion, we have shown that Flv alleviates Px-induced neurotoxicity *in vitro* and Sig-1R is involved in this alleviation mechanism. Flv has been commonly used in clinical practice, including in patients with breast cancer. Thus, a detailed evaluation of Flv effects (not only on depression but also other neurological symptoms, including cognitive function) will be required in clinical practice for the numerous applicable symptoms.




Fig. 2. Flv alleviates Px-induced ER stress-mediated apoptosis. (a–c) SK-N-SH cells were pre-treated with or without 10 μ g/ml Flv for 12 h followed by a 1- μ M Px treatment with or without 10 μ g/ml Flv for 24 h. CHOP, caspase 4, and caspase 3 were detected by Western blotting. GAPDH was used as an internal control. * p < 0.05, ** p < 0.01 (one-way ANOVA followed by Tukey–Kramer test). (d and e) SK-N-SH cells were treated with 10 μ g/ml Flv for 12 h and 24 h. Sig-1R was detected by Western blotting. GAPDH was used as an internal control. * p < 0.05, ** p < 0.01 (Student's *t*-test).




Fig. 3. Flv alleviates Px-induced neurotoxicity through Sig-1R. SK-N-SH cells were pre-treated with or without 10 μ g/ml Flv for 12 h followed by a 1 μ M Px, 10 μ g/ml Flv, and 1 μ M Px/10 μ g/ml Flv, with or without 1 μ M NE100 treatment for 24 h. The viability was assessed using an MTS assay. The relative ratio of the absorbance compared with the vehicle control absorbance is indicated. Histograms show the mean \pm SD from six independent experiments. * p < 0.05, ** p < 0.01 (one-way ANOVA followed by Tukey–Kramer test).

Acknowledgments

We thank Ms. Mieko Kitamura for technical assistance. This work was supported by a Grant-in-Aid for Scientific Research (C) (25461729) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.bbrep.2015.09.014>.

References

- [1] T.A. Ahles, A.J. Saykin, C.T. Furstenberg, B. Cole, L.A. Mott, K. Skalla, M. B. Whedon, S. Bivens, T. Mitchell, E.R. Greenberg, P.M. Silberfarb, Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma, *J. Clin. Oncol.* 20 (2002) 485–493.
- [2] C.B. Brezden, K.A. Phillips, M. Abdolell, T. Bunston, I.F. Tannock, Cognitive function in breast cancer patients receiving adjuvant chemotherapy, *J. Clin. Oncol.* 18 (2000) 2695–2701.
- [3] F. Joly, O. Rigal, S. Noal, B. Giffard, Cognitive dysfunction and cancer: which consequences in terms of disease management? *Psychooncology* 20 (2011) 1251–1258.
- [4] S.B. Schagen, F.S. van Dam, M.J. Muller, W. Boogerd, J. Lindeboom, P.F. Bruning, Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma, *Cancer* 85 (1999) 640–650.
- [5] M. Monje, J. Dietrich, Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis, *Behav. Brain Res.* 227 (2012) 376–379.
- [6] C.D. Aluise, S. Miriyala, T. Noel, R. Sultana, P. Jungsuwadee, T.J. Taylor, J. Cai, W. M. Pierce, M. Vore, J.A. Moscow, D.K. St Clair, D.A. Butterfield, 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF- α release: implications for the reactive oxygen species-mediated mechanisms of chemobrain, *Free Radic. Biol. Med.* 50 (2011) 1630–1638.
- [7] J.S. Myers, The possible role of cytokines in chemotherapy-induced cognitive deficits, *Adv. Exp. Med. Biol.* 678 (2010) 119–123.
- [8] S.M. Stemmer, J.C. Stears, B.S. Burton, R.B. Jones, J.H. Simon, White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support, *AJNR Am. J. Neuroradiol.* 15 (1994) 1267–1273.
- [9] S. Deprez, F. Amant, A. Smeets, R. Peeters, A. Leemans, W. Van Hecke, J. S. Verhoeven, M.R. Christiaens, J. Vandenbergh, M. Vandenbulcke, S. Sunaert, Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning, *J.*

- Clin. Oncol. 30 (2012) 274–281.
- [10] D.H. Silverman, C.J. Dy, S.A. Castellon, J. Lai, B.S. Pio, L. Abraham, K. Waddell, L. Petersen, M.E. Phelps, P.A. Ganz, Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy, *Breast Cancer Res. Treat.* 103 (2007) 303–311.
- [11] M.A. Jordan, L. Wilson, Microtubules and actin filaments: dynamic targets for cancer chemotherapy, *Curr. Opin. Cell Biol.* 10 (1998) 123–130.
- [12] L.M. Thornton, W.E. Carson 3rd, C.L. Shapiro, W.B. Farrar, B.L. Andersen, Delayed emotional recovery after taxane-based chemotherapy, *Cancer* 113 (2008) 638–647.
- [13] A. Gangloff, W.A. Hsueh, A.L. Kesner, D.O. Kiesewetter, B.S. Pio, M.D. Pegram, M. Beryt, A. Townsend, J. Czernin, M.E. Phelps, D.H. Silverman, Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel, *J. Nucl. Med.* 46 (2005) 1866–1871.
- [14] J.J. Hoozemans, E.S. van Haastert, P. Eikelenboom, R.A. de Vos, J.M. Rozemuller, W. Scheper, Activation of the unfolded protein response in Parkinson's disease, *Biochem. Biophys. Res. Commun.* 354 (2007) 707–711.
- [15] J.J. Hoozemans, E.S. van Haastert, D.A. Nijholt, A.J. Rozemuller, W. Scheper, Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease, *Neurodegener. Dis.* 10 (2012) 212–215.
- [16] T. Katayama, K. Imaizumi, N. Sato, K. Miyoshi, T. Kudo, J. Hitomi, T. Morihara, T. Yoneda, F. Gomi, Y. Mori, Y. Nakano, J. Takeda, T. Tsuda, Y. Itoyama, O. Murayama, A. Takashima, P. George-Hyslop, M. Takeda, M. Tohyama, Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response, *Nat. Cell Biol.* 1 (1999) 479–485.
- [17] T. Kudo, M. Okumura, K. Imaizumi, W. Araki, T. Morihara, H. Tanimukai, E. Kamagata, N. Tabuchi, R. Kimura, D. Kanayama, A. Fukumori, S. Tagami, M. Okochi, M. Kubo, H. Tani, M. Tohyama, T. Tabira, M. Takeda, Altered localization of amyloid precursor protein under endoplasmic reticulum stress, *Biochem. Biophys. Res. Commun.* 344 (2006) 525–530.
- [18] Y. Sakagami, T. Kudo, H. Tanimukai, D. Kanayama, T. Omi, K. Horiguchi, M. Okochi, K. Imaizumi, M. Takeda, Involvement of endoplasmic reticulum stress in tauopathy, *Biochem. Biophys. Res. Commun.* 430 (2013) 500–504.
- [19] H. Tanimukai, D. Kanayama, T. Omi, M. Takeda, T. Kudo, Paclitaxel induces neurotoxicity through endoplasmic reticulum stress, *Biochem. Biophys. Res. Commun.* 437 (2013) 151–155.
- [20] T. Kudo, S. Kanemoto, H. Hara, N. Morimoto, T. Morihara, R. Kimura, T. Tabira, K. Imaizumi, M. Takeda, A molecular chaperone inducer protects neurons from ER stress, *Cell Death Differ.* 15 (2008) 364–375.
- [21] Y. Oida, H. Izuta, A. Oyagi, M. Shimazawa, T. Kudo, K. Imaizumi, H. Hara, Induction of BiP, an ER-resident protein, prevents the neuronal death induced by transient forebrain ischemia in gerbil, *Brain Res.* 1208 (2008) 217–224.
- [22] Y. Inokuchi, Y. Nakajima, M. Shimazawa, T. Kurita, M. Kubo, A. Saito, H. Sajiki, T. Kudo, M. Aihara, K. Imaizumi, M. Araie, H. Hara, Effect of an inducer of BiP, a molecular chaperone, on endoplasmic reticulum (ER) stress-induced retinal cell death, *Investig. Ophthalmol. Vis. Sci.* 50 (2009) 334–344.
- [23] S. Hino, S. Kondo, K. Yoshinaga, A. Saito, T. Murakami, S. Kanemoto, H. Sekiya, K. Chihara, Y. Aikawa, H. Hara, T. Kudo, T. Sekimoto, T. Funamoto, E. Chosa, K. Imaizumi, Regulation of ER molecular chaperone prevents bone loss in a murine model for osteoporosis, *J. Bone Miner. Metab.* 28 (2010) 131–138.
- [24] Y. Oida, J. Hamanaka, K. Hyakkoku, M. Shimazawa, T. Kudo, K. Imaizumi, T. Yasuda, H. Hara, Post-treatment of a BiP inducer prevents cell death after middle cerebral artery occlusion in mice, *Neurosci. Lett.* 484 (2010) 43–46.
- [25] T. Nakanishi, M. Shimazawa, S. Sugitani, T. Kudo, S. Imai, Y. Inokuchi, K. Tsuruma, H. Hara, Role of endoplasmic reticulum stress in light-induced photoreceptor degeneration in mice, *J. Neurochem.* 125 (2013) 111–124.
- [26] T. Omi, H. Tanimukai, D. Kanayama, Y. Sakagami, S. Tagami, M. Okochi, T. Morihara, M. Sato, K. Yanagida, A. Kitasyoji, H. Hara, K. Imaizumi, T. Maurice, N. Chevallier, S. Marchal, M. Takeda, T. Kudo, Fluvoxamine alleviates ER stress via induction of Sigma-1 receptor, *Cell Death Dis.* 5 (2014) e1332.
- [27] N. Narita, K. Hashimoto, S. Tomitaka, Y. Minabe, Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain, *Eur. J. Pharmacol.* 307 (1996) 117–119.
- [28] C.S. Lee, Y.J. Kim, E.R. Jang, W. Kim, S.C. Myung, Fluoxetine induces apoptosis in ovarian carcinoma cell line OVCAR-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB, *Basic Clin. Pharmacol. Toxicol.* 106 (2010) 446–453.
- [29] Y. Levkovitz, I. Gil-Ad, E. Zeldich, M. Dayag, A. Weizman, Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement, *J. Mol. Neurosci.* 27 (2005) 29–42.
- [30] V. Kannen, H. Hintzsche, D.L. Zanette, W.A. Silva Jr., S.B. Garcia, A.M. Waaga-Gasser, H. Stopper, Antiproliferative effects of fluoxetine on colon cancer cells and in a colonic carcinogen mouse model, *PLoS One* 7 (2012) e50043.
- [31] T. Hosoi, T. Miyahara, T. Kayano, S. Yokoyama, K. Ozawa, Fluvoxamine attenuated endoplasmic reticulum stress-induced leptin resistance, *Front. Endocrinol.* 3 (2012) 12.
- [32] T. Hayashi, T. Maurice, T.P. Su, Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration, *J. Pharmacol. Exp. Ther.* 293 (2000) 788–798.
- [33] T. Hayashi, T. Su, The sigma receptor: evolution of the concept in neuropsychopharmacology, *Curr. Neuropharmacol.* 3 (2005) 267–280.
- [34] T. Hayashi, T.P. Su, Regulating ankyrin dynamics: Roles of sigma-1 receptors, *Proc. Natl. Acad. Sci. USA* 98 (2001) 491–496.
- [35] T. Hayashi, T.P. Su, Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival, *Cell* 131 (2007) 596–610.
- [36] K. Hashimoto, K. Ishiwata, Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals, *Curr. Pharm. Des.* 12 (2006) 3857–3876.
- [37] T. Hayashi, S.Y. Tsai, T. Mori, M. Fujimoto, T.P. Su, Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders, *Expert Opin. Ther. Targets* 15 (2011) 557–577.
- [38] T. Niitsu, M. Iyo, K. Hashimoto, Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases, *Curr. Pharm. Des.* 18 (2012) 875–883.
- [39] S.M. Stahl, The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? *J. Clin. Psychiatry* 69 (2008) 1673–1674.
- [40] S. Katsuyama, K. Sato, T. Yagi, Y. Kishikawa, H. Nakamura, Effects of repeated milnacipran and fluvoxamine treatment on mechanical allodynia in a mouse paclitaxel-induced neuropathic pain model, *Biomed. Res.* 34 (2013) 105–111.
- [41] D.J. DeGracia, H.L. Montie, Cerebral ischemia and the unfolded protein response, *J. Neurochem.* 91 (2004) 1–8.